From Indonesia to Malaysia: Elitery Accelerates Regional Expansion with Local Partnership in Malaysia
"Our expansion into Malaysia through our subsidiary, Elitery Global Technology Sdn. Bhd., marks a strategic move to penetrate the regional market and accelerate global growth. Through the acquisition of Iloken System Sdn. Bhd., we have secured a local partner with highly competent talent, a proven business track record, and relevant experience in delivering critical digital infrastructure projects in Malaysia," said Kresna Adiprawira, President Director of Elitery.
According to Kresna, Elitery's decision to acquire rather than build from the ground up was driven by the strategic advantages Iloken System brings. Iloken System already has a solid operational foundation and significant potential for joint growth. The company has successfully developed emergency response systems (line one emergency system) and flood warning systems in Malaysia, along with a strong portfolio of recurring clients.
The decision to expand into Malaysia was based on strategic analysis of the country's market potential and its digital ecosystem readiness. Malaysia is currently experiencing rapid growth in the fields of cloud computing, artificial intelligence (AI), and cyber security. According to the report Gartner: Information Security, Worldwide Forecast, 1Q25 Update, Malaysia's spending on information security is projected to increase by 84% between 2023 and 2029, driven by escalating digital threats and nationwide transformation initiatives. Meanwhile, the public cloud market is expected to reach USD 2.82 billion by 2025. In addition, Statista Market Insights: Generative AI – Malaysia (2024) projects that the generative AI market in Malaysia will grow at a compound annual growth rate (CAGR) of 36.98% from 2025 to 2031, starting at an estimated USD 333 million.
This momentum is no coincidence. Leading global technology companies such as Google, AWS, Oracle, and Microsoft have committed multi-billion-dollar investments in Malaysia, establishing data centers, public cloud infrastructure, and AI capabilities. With progressive digital policies and attractive investment incentives from the government, Malaysia is rapidly positioning itself as a strategic hub for digital transformation in Southeast Asia.
At the same time, the growing demand for reliable technology partners has become increasingly crucial. Local institutions and industries in Malaysia are actively looking for digital transformation partners with strong expertise in cloud systems integration, IT automation, and data protection. Elitery sees this as a strategic opportunity to bring significant value, leveraging its proven track record in the Indonesian market.
"We believe this marks the beginning of a new chapter for Elitery, transitioning from a national leader into a regional enabler of digital change. With collaboration and innovation at our core, we are committed to supporting Southeast Asia's digital transformation journey. " Kresna concluded.
About Elitery:
Elitery (PT. Data Sinergitama Jaya Tbk) is an IT managed services company specializing in information technology, particularly in cloud technology. With over 14 years of experience, we are committed to delivering excellent services to our clients. Backed by a solid reputation, Elitery is trusted by global cloud service providers such as Google Cloud as a go-to-market partner in Indonesia.
Since 2011, Elitery has handled numerous mission-critical systems accessed by tens of millions of users daily. Our clientele spans various sectors, both private and public. With our proven experience and capabilities, we are confident in our ability to serve as a reliable partner for your organization's digital transformation journey.
In both 2023 and 2024, Elitery was honored with the prestigious Public Sector Partner of the Year – Asia Pacific award from Google Cloud for two consecutive years. In 2024, Elitery also officially joined the Google Cloud Managed Security Services Provider (MSSP) initiative marking a strategic move to enhance our cybersecurity services.
Throughout 2024, Elitery achieved several other significant milestones, including receiving the Indonesia Best CX-EX Strategy Award 2024 from SWA, and being recognized as a Great Place to Work (GPTW) 2024, reflecting our commitment to strong governance and an inclusive, collaborative work environment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![[Lee Byung-jong] Time for Korea's brain gain](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F07%2F17%2Fnews-p.v1.20250717.a8050bbc61a64e1d9d7de93ad98b4acc_T1.jpg&w=3840&q=100)
![[Lee Byung-jong] Time for Korea's brain gain](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
4 hours ago
- Korea Herald
[Lee Byung-jong] Time for Korea's brain gain
There was a time when South Korean scientists and engineers left their country in droves, seeking better research environments and more rewarding careers abroad —especially in the United States. For decades, this outflow of talent, often referred to as brain drain, was seen as a symptom of Korea's limited scientific infrastructure and rigid institutional culture. But today, the situation is changing. South Korea has emerged as a serious player in research and development, and its universities and companies are becoming increasingly competitive. Now, many of those once-lost talents are coming home — and more could follow. This trend could accelerate in light of policy shifts in the United States. The Trump administration has cut research funding and accused academic institutions of being "liberal strongholds,' pushing many scholars to consider opportunities abroad. As a result, countries around the world have begun courting scientists and academics disillusioned with the American system, offering them better support, autonomy and respect for their work. Canada, for example, has positioned itself as a haven for displaced US-based academics, offering generous funding and robust institutional support. The University of Toronto has successfully recruited several leading researchers from American universities in recent years. Similar efforts are underway in Europe. Aix-Marseille University in France recently offered 15 positions specifically aimed at US-based scholars. Across the continent, institutions in the UK, Germany and elsewhere are actively attracting American talent, especially as diplomatic and trade tensions with the US continue to rise. China is another key player in this new global race for talent. Armed with extensive government funding, a vast research infrastructure, and a clear national strategy, China has been aggressively courting global experts. Many China-born scientists and engineers, educated and employed in the US, are returning home, driven partly by growing anti-China sentiment in the US. However, China's ambitions face a critical limitation: a lack of academic freedom. For many international scholars, concerns about censorship and political interference make China a less appealing destination. Hong Kong once offered an alternative, but increasing control from Beijing has narrowed that window as well. In this global context, South Korea stands out as a country with both the motivation and the means to benefit from the US brain drain. Although it is still an emerging power in basic sciences, Korea has made impressive strides. Its universities may not yet be counted among the global elite, but their quality has improved dramatically. World-class research institutions like KAIST, Postech and the Institute for Basic Science are helping close the gap. Historically, most researchers returning to Korea have been Korean nationals who studied or worked abroad. Foreign scholars remain a rarity in Korean academia, largely due to systemic challenges: relatively low compensation, a rigid academic culture, hierarchical management in companies and significant language barriers. Many universities and research institutions still prioritize Korean-language communication and maintain promotion systems that can be opaque or overly rigid, discouraging interdisciplinary and creative work. Despite these challenges, Korea has the potential to become a global R&D hub. It invests over 4 percent of its gross domestic product in R&D — among the highest rates in the world — and the government has long recognized science and technology as essential to national development. Major conglomerates such as Samsung, SK, Hyundai, LG and Posco pour enormous sums into their research centers and also support affiliated institutions like Postech. The government-run Institute for Basic Science, launched in 2011, collaborates with these players in key fields including biotechnology, AI, semiconductors, physics, robotics and battery research. These investments are already producing results. The IBS has recruited world-class talent such as Kim Ki-moon, an expert in supramolecular chemistry, and Noh Do-young, a leader in advanced X-ray science — both of whom returned from prestigious US laboratories. At KAIST, Cho Kwang-hyun, a systems biology expert trained in the US, is leading cutting-edge research. Foreign talent, while still rare, is also starting to arrive. One standout is Rodney S. Ruoff, an American chemist renowned for his work in carbon materials, who joined IBS to lead nanomaterials research. He praised IBS for offering 'unprecedented freedom' compared to US institutions. Institutions across Korea are making efforts to attract more of this kind of talent. The Daegu Gyeongbuk Institute of Science and Technology, for example, is actively recruiting global doctoral-level researchers in AI as part of a joint initiative with the Ministry of Science and ICT. Its postdoctoral fellowship program offers highly attractive compensation — up to 90 million won ($ 64,700) annually — along with research funding and opportunities for industry collaboration. These moves are designed not only to build domestic expertise but also to internationalize Korea's research environment. Ultimately, all these efforts toward brain gain aim to strengthen Korea's global standing in R&D, which still lags behind its industrial and manufacturing dominance. While Samsung and other Korean brands are global market leaders, their long-term success depends on innovation rooted in foundational science and technology. However, one major domestic challenge remains: attracting young Korean talent to scientific fields. An increasing number of top students are opting for medical school over careers in engineering or science, seeking greater job stability and social prestige. For a country still waiting for its first Nobel Prize in science (it has only won in peace and literature), this trend is troubling. Yet, the momentum behind Korea's brain gain strategy may help reverse this. By showcasing world-class research, international partnerships, and success stories of returnees and foreign scholars, Korea can inspire the next generation of homegrown scientists — and attract the best minds from around the world.
Korea Herald
10 hours ago
- Korea Herald
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
SEONGNAM, South Korea, July 17, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. The candidate incorporates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu' to enhance protective efficacy. SK bioscience previously utilized adjuvants in its COVID-19 vaccine, 'SKYCovione', and now seeks to expand this technology to influenza vaccines as part of its broader platform strategy. NBP607B contains an adjuvant developed by the Vaccine Formulation Institute (VFI), a Swiss-based non-profit vaccine research organization. Comprising multiple immune-boosting components, the adjuvant is expected to induce strong immune responses and antibody production in elderly individuals. SK bioscience has proactively conducted non-clinical studies since 2023 and reported promising results. The Phase 1/2 clinical trial is scheduled to begin during the upcoming Northern Hemisphere flu season, enrolling approximately 320 older adults in Korea and abroad. The study will evaluate the vaccine's immunogenicity and safety compared to an approved high-immunogenicity flu vaccine, with interim results expected by 2027. This marks the first attempt by a Korean company to submit an IND to develop a high-immunogenicity influenza vaccine using an adjuvant. If successful, the company plans to leverage the platform for other vaccines and establish a competitive edge in the global high-value vaccine market. The development aligns with global health authorities' increasing recommendations for enhanced flu vaccines in high-risk groups. The U.S. Centers for Disease Control and Prevention (CDC)'s Advisory Committee on Immunization Practices (ACIP) recommends high-dose or adjuvanted influenza vaccines for adults aged 65 and older. The World Health Organization (WHO) also supports the use of adjuvanted vaccines for vulnerable populations. In Korea, the Korea Disease Control and Prevention Agency (KDCA) has indicated that domestically developed high-immunogenicity vaccines may be considered for inclusion in the National Immunization Program (NIP) if they meet appropriate criteria. According to market research firm Mordor Intelligence, the global vaccine market is projected to grow from USD 83.9 billion in 2025 to USD 114.8 billion in 2030, with an average annual growth rate of 6.5%. Demand for high-immunogenicity vaccines is expected to rise continuously due to global aging and the increasing number of immunocompromised individuals and those with chronic illnesses. SKYCellflu, SK bioscience's existing cell-based influenza vaccine, has already been recognized for its innovation. It became the world's first cell-based flu vaccine to receive prequalification (PQ) from the WHO and is currently approved in 11 countries, with supply through international procurement programs by United Nations Children's Fund (UNICEF) and Pan American Health Organization (PAHO). Jaeyong Ahn, CEO of SK bioscience, said, "We believe the combination of our proven SKYCellflu platform and our experience in adjuvanted vaccine development positions us well for success. We aim to establish a differentiated presence in the high-immunogenicity vaccine market while building a flexible platform for future infectious disease preparedness."
Korea Herald
17 hours ago
- Korea Herald
GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam
YONGIN, South Korea, July 17, 2025 /PRNewswire/ -- GC Biopharma ( a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received marketing authorization from the Drug Administration of Vietnam (DAV). Following domestic approval in 2020 and WHO Pre-Qualification (PQ) in 2023, GC Biopharma has been accelerating individual country registrations as part of its dual-track strategy—pursuing both global procurement channels and direct market entry initiatives. To obtain approval in Vietnam, GC Biopharma conducted local clinical trials to establish the product's safety and immunogenicity. This achievement highlights the company's ability to meet the increasingly stringent regulatory standards set by DAV. As a vaccine administered primarily to children, quality certification holds particular importance in the varicella segment. GC Biopharma plans to establish stable annual revenue in Vietnam by leveraging its local affiliate to engage directly in sales activities, in consideration of the country's private market-oriented vaccine distribution system. From 2018 to 2021, Vietnam's private vaccine market recorded a compound annual growth rate (CAGR) of 32%, reaching approximately USD 300 million in 2021. Varicella vaccines accounted for nearly 10% of the private market [1], with demand for private vaccinations continuing to grow steadily. "This marketing authorization represents more than a product export—it is the result of a localization strategy and a significant step toward expansion in Southeast Asia," said Jae Woo Lee, Head of Development Department at GC Biopharma. "We will continue to strengthen our position as a trusted vaccine brand by delivering clinical and quality standards that meet global expectations." BARYCELA is a live attenuated varicella vaccine developed by GC Biopharma using its proprietary MAV/06 virus strain. The vaccine is characterized by high viral titer and manufacturing yield. Notably, BARYCELA is the world's first varicella vaccine produced without antibiotics, utilizing a fully aseptic manufacturing process. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo ® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Sohee Kim Yelin Jun
